<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958423</url>
  </required_header>
  <id_info>
    <org_study_id>B412201524615</org_study_id>
    <nct_id>NCT02958423</nct_id>
  </id_info>
  <brief_title>tDCS Versus tsDCS for Endometriosis-related Chronic Pelvic Pain Treatment</brief_title>
  <acronym>DCSErCPP</acronym>
  <official_title>Transcranial Direct Current Stimulation (tDCS) vs Trans-spinal Direct Current Stimulation (tsDCS) for Endometriosis-related Chronic Pelvic Pain Treatment: A Single Center, Prospective, Randomized, Controlled, Parallel Group Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean Schoenen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the analgesic effect of 2 mA anodal direct current
      stimulation on the right primary motor cortex (M1) (tDCS) with a similar stimulation on the
      spine (D10) (tsDCS) in healthy volunteers (HV) followed by a pilot study in patients
      suffering of endometriosis-related chronic pelvic pain (CPP)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - 2 groups of 5 HV will receive tDCS or tsDCS (2mA, anodal, 20min) and the thermonociceptive
      threshold will be measured before and after the stimulation over the abdomen (hypogastric).
      The HAD scale and SF-36 will also be tested.

      The treatment(s) that produces the greatest increase in pain thresholds will be chosen to
      treat 10 patients.

      - 10 patients suffering from endometriosis-related chronic pelvic pain will be treated by the
      most efficient treatment (tDCS or tsDCS) for 4 weeks (5 daily 20-min sessions per week), or,
      if no treatment modality was superior in HV, 5 patients will be treated by tDCS and 5 by
      tsDCS. Patients will fill in daily a dedicated diary 2 weeks before treatment, during
      the4-week treatment period and after this period as long as their pain level remains below
      80% of their baseline pain intensity (VAS). Analgesic intake will also be monitored as well
      as HAD and SF-36 scores.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antalgic effect of direct current stimulation by measuring Quantitative Sensory Testing (QST)</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Endometriosis</condition>
  <condition>Pelvic Pain</condition>
  <condition>Transcranial Direct Current Stimulation</condition>
  <condition>Spinal Cord Stimulation</condition>
  <arm_group>
    <arm_group_label>Transcranial DCS Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transspinal DCS Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcranial DCS CPP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transspinal DCS CPP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial DCS Healthy Volunteers</intervention_name>
    <description>The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers</description>
    <arm_group_label>Transcranial DCS Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transspinal DCS Healthy Volunteers</intervention_name>
    <description>The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers</description>
    <arm_group_label>Transspinal DCS Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial DCS CPP patients</intervention_name>
    <description>The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients</description>
    <arm_group_label>Transcranial DCS CPP patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transspinal DCS CPP patients</intervention_name>
    <description>The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients</description>
    <arm_group_label>Transspinal DCS CPP patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HV: good health.

          -  CPP patients: surgical diagnosis of endometriosis within the last 10 years; diagnosis
             of chronic pelvic pain (according to ACOG); mean VAS pain score &gt;4 during severe
             episodes.

        Exclusion Criteria:

          -  HV: chronic pain disorder; no regular medication or illicit drug use.

          -  CPP patients: pregnancy; other medical or psychiatric condition interfering with
             pelvic pain assessment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Nisolle, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Liege</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Fataki Likale, Intern</last_name>
    <phone>0032496721921</phone>
    <email>m.fataki@student.ulg.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Schoenen, Professor</last_name>
    <email>jschoenen@ulg.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departments of Gynecology &amp; Neurology. CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Schoenen, MD, PhD</last_name>
      <phone>+3242238663</phone>
      <email>jschoenen@ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Michel Fataki Likale, MD</last_name>
      <phone>+3242256111</phone>
      <email>mfataki@student.ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Nisolle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Jean Schoenen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>anonymized data will be made available on request via e-mail</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

